Daratumumab: Uses, Side Effects & Warnings

• Daratumumab is a monoclonal antibody approved for treating multiple myeloma and light chain amyloidosis.
• It targets the CD38 protein on cancer cells, leading to their destruction through various immune mechanisms.
• Common side effects include infusion-related reactions, fatigue, nausea, and respiratory infections.
• Serious warnings involve potential for infusion reactions, hepatitis B reactivation, and interference with blood tests.
• Patients receiving Daratumumab require careful monitoring and adherence to specific treatment schedules and precautions.

What is Daratumumab Used For?

Daratumumab is a targeted therapy primarily indicated for the treatment of specific hematological malignancies. Its primary application is in patients with multiple myeloma, a cancer of plasma cells, where it is used both as a monotherapy and in combination with other agents. It is approved for newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant, as well as for relapsed or refractory multiple myeloma, meaning the cancer has returned or has not responded to previous treatments.

Beyond multiple myeloma, Daratumumab uses also extend to the treatment of newly diagnosed light chain (AL) amyloidosis. This rare and serious disease occurs when abnormal proteins (amyloid) produced by plasma cells accumulate in organs, impairing their function. In AL amyloidosis, Daratumumab is typically used in combination with other medications to reduce the production of these harmful proteins and improve organ function. The mechanism of action involves binding to CD38, a protein highly expressed on multiple myeloma cells and other cells, leading to direct cell death and immune-mediated destruction of cancer cells.

Common and Serious Side Effects

Like all medications, Daratumumab can cause a range of side effects, some of which are common and manageable, while others can be serious and require immediate medical attention. Understanding these potential reactions is a crucial part of Daratumumab drug information for patients and healthcare providers.

Common side effects often include:

• Infusion-related reactions: These are very common, especially during the first infusion, and can include symptoms like fever, chills, nausea, cough, shortness of breath, and headache. Pre-medication is typically administered to mitigate these reactions.
• Fatigue: Patients frequently report feeling tired or lacking energy.
• Nausea and diarrhea: Gastrointestinal disturbances are also common.
• Upper respiratory tract infection: Increased susceptibility to infections such as bronchitis or pneumonia.
• Peripheral neuropathy: Numbness, tingling, or pain in the hands and feet, particularly when Daratumumab is used in combination with other neurotoxic agents.

Serious Daratumumab side effects, though less frequent, can be significant. These include severe infusion-related reactions that may require stopping the infusion, serious infections (e.g., pneumonia, sepsis) due to its immunosuppressive effects, and a decrease in blood cell counts (cytopenias), such as neutropenia (low white blood cells) and thrombocytopenia (low platelets). Additionally, Daratumumab can interfere with certain blood tests, specifically indirect antiglobulin tests (Coombs test) and serum protein electrophoresis, which can complicate blood transfusions or monitoring of disease progression. Patients should always inform their healthcare providers about all symptoms experienced during treatment.

Important Warnings and Precautions

Several important Daratumumab warnings and precautions must be considered before and during treatment to ensure patient safety and optimize outcomes. Healthcare providers carefully assess a patient’s medical history and current health status to minimize risks associated with this potent medication.

Infusion-Related Reactions (IRRs)

Infusion-related reactions are a significant concern with Daratumumab, occurring in a high percentage of patients, particularly during the first infusion. These reactions can range from mild to severe and may include symptoms like chills, shortness of breath, headache, nausea, and rash. To manage and prevent IRRs, patients receive pre-medications such as corticosteroids, antihistamines, and antipyretics before each infusion. Close monitoring during and after infusions is essential, and the infusion rate may be adjusted or temporarily halted if a reaction occurs. Patients are also advised to report any symptoms promptly.

Risk of Infections and Hepatitis B Reactivation

Daratumumab can suppress the immune system, increasing the risk of serious infections, including bacterial, viral, and fungal infections. Patients should be monitored for signs and symptoms of infection throughout treatment. Furthermore, there is a risk of hepatitis B virus (HBV) reactivation in patients who are carriers of the virus. All patients should be screened for HBV infection before starting Daratumumab treatment. If a patient tests positive for HBV, antiviral prophylaxis may be initiated to prevent reactivation, and close monitoring for signs of HBV reactivation is necessary during and for several months after treatment.

Another critical warning involves the potential for interference with cross-matching and red blood cell antibody screening. Daratumumab binds to CD38 on red blood cells, which can lead to a false positive indirect Coombs test. This interference can complicate blood transfusions, making it difficult to find compatible blood. Patients should carry a card indicating they are receiving Daratumumab to inform healthcare professionals in case of an emergency transfusion. Healthcare providers must be aware of this interference and implement appropriate measures, such as phenotyping and genotyping, to ensure safe blood transfusions.

Daratumumab Treatment Details and Patient Guide

Understanding the specifics of treatment with Daratumumab is crucial for patients and their caregivers. This section provides an overview of Daratumumab treatment details, including administration, dosage, and what a patient can expect throughout their therapeutic journey. Adherence to the prescribed regimen and proactive communication with the healthcare team are key to successful outcomes.

Administration and Dosage Schedule

Daratumumab is administered intravenously (into a vein) or subcutaneously (under the skin), depending on the specific formulation and indication. The intravenous formulation typically requires longer infusion times, especially for the initial doses, which can be several hours. The subcutaneous formulation offers a shorter administration time. The dosage and frequency of administration vary based on the patient’s condition, weight, and whether it’s used as monotherapy or in combination with other drugs. Typically, treatment begins with weekly infusions, gradually transitioning to less frequent schedules (e.g., every two or four weeks) over time. The full Daratumumab patient guide will outline the specific schedule tailored to each individual.

Patients should be prepared for the time commitment involved with infusions, particularly in the initial phases. Pre-medications are given before each infusion to reduce the risk of infusion-related reactions. Post-infusion medications may also be prescribed to manage potential side effects. It is vital for patients to attend all scheduled appointments and communicate any missed doses or concerns to their healthcare team immediately. Regular blood tests and other assessments will be conducted throughout the treatment period to monitor the patient’s response to therapy and manage any emerging side effects.

Monitoring and Patient Support

Throughout Daratumumab treatment, patients undergo regular monitoring to assess treatment efficacy and manage side effects. This includes frequent blood counts to check for cytopenias, liver and kidney function tests, and monitoring for signs of infection. Patients are encouraged to report any new or worsening symptoms promptly to their healthcare provider. Support for patients extends beyond medical monitoring; it also includes managing the emotional and psychological impact of cancer treatment.

A comprehensive Daratumumab patient guide often includes advice on managing fatigue, maintaining nutrition, and preventing infections. Patients should be educated on the importance of good hygiene, avoiding crowded places, and reporting any fever or signs of infection immediately. Counseling or support groups can also be beneficial for patients coping with the challenges of cancer therapy. While alternative or complementary therapies might be discussed, it is important to remember that such information is supportive only and does not replace medical treatment with Daratumumab or other prescribed medications.

Frequently Asked Questions

How does Daratumumab work to fight cancer?

Daratumumab is a monoclonal antibody that targets the CD38 protein, which is highly expressed on multiple myeloma cells and other cancer cells. By binding to CD38, Daratumumab triggers various immune mechanisms to destroy these cells. This includes direct cell death (apoptosis), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), all working together to eliminate the cancerous cells from the body.

What should I do if I experience side effects during Daratumumab treatment?

If you experience any side effects during Daratumumab treatment, it is crucial to inform your healthcare team immediately. For common side effects like fatigue or nausea, your doctor may suggest supportive care or adjustments to your treatment plan. For more serious reactions, especially infusion-related symptoms or signs of infection, prompt medical attention is necessary. Never hesitate to report symptoms, as early intervention can help manage adverse events effectively and ensure your safety.

Can Daratumumab affect other medical conditions or medications?

Yes, Daratumumab can interact with other medical conditions and medications. It can suppress the immune system, increasing the risk of infections, and may reactivate latent viruses like Hepatitis B. It also interferes with certain blood tests, making blood transfusions more complex. Always provide your healthcare provider with a complete list of all your current medications, supplements, and medical conditions to ensure safe and effective treatment and to avoid potential drug interactions or complications.